10.34

2.36% -0.25

After Hours: 11.07 0.73 +7.06%

Cartesian Therapeutics Inc (RNAC)

Overview News Price History Option Chain Financials Discussions Forecast

Cartesian Therapeutics Inc stock is traded at $10.34, with a volume of 124.55K. It is down -2.36% in the last 24 hours and up +77.05% over the past month. Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.

Previous Close:

$10.59

Open:

$10.64

24h Volume:

124.55K

Relative Volume:

0.44

Market Cap:

$303.80M

Revenue:

$1.78M

Net Income/Loss:

$-151.77M

P/E Ratio:

-1.7833

EPS:

-5.7981

Net Cash Flow:

$-79.40M

1W Performance:

+7.26%

1M Performance:

+77.05%

6M Performance:

+46.88%

1Y Performance:

-7.76%

1-Day Range:

$10.26

$10.84

1-Week Range:

$9.26

$10.95

52-Week Range:

$5.60

$15.57

Cartesian Therapeutics Inc Stock (RNAC) Company Profile

Name

Cartesian Therapeutics Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

301-348-8698

Address

7495 NEW HORIZON WAY, FREDERICK

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

RNAC's Discussions on Twitter

Compare RNAC vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RNAC Cartesian Therapeutics Inc	10.34	306.16M	1.78M	-151.77M	-79.40M	-5.7981
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-09-26	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Jul-09-25	Initiated	Wedbush	Outperform
Dec-19-24	Initiated	BTIG Research	Buy
Aug-06-24	Initiated	TD Cowen	Buy
Jul-02-24	Downgrade	Oppenheimer	Outperform → Perform
Jun-04-24	Initiated	Oppenheimer	Outperform
May-24-24	Initiated	Mizuho	Buy
Apr-23-24	Reiterated	H.C. Wainwright	Buy
Apr-23-24	Initiated	Leerink Partners	Outperform
Aug-18-23	Downgrade	SVB Securities	Outperform → Market Perform
Jun-14-22	Reiterated	Needham	Buy
Jun-06-22	Initiated	SVB Leerink	Outperform
Jun-15-21	Initiated	BTIG Research	Buy
Jan-26-21	Upgrade	Mizuho	Neutral → Buy
Oct-01-20	Downgrade	Mizuho	Buy → Neutral
Oct-01-20	Downgrade	William Blair	Outperform → Mkt Perform
Jun-12-20	Downgrade	Stifel	Buy → Hold
Apr-28-20	Initiated	H.C. Wainwright	Buy
Jan-29-20	Initiated	Cantor Fitzgerald	Overweight
Jan-21-20	Initiated	William Blair	Outperform
Jun-27-18	Initiated	Janney	Buy
Mar-30-17	Reiterated	UBS	Buy

View All

Cartesian Therapeutics Inc Stock (RNAC) Latest News

Jul 01, 2026

RNACCartesian Therapeutics Inc Latest SEC Filings - Finviz

Jul 01, 2026

Jun 29, 2026

Cartesian Therapeutics (RNAC) Q1 2026 Earnings: Wider-than-Expected Loss as Clinical-Stage Pipeline AdvancesOne-Time Gain Impact - dars.gov.et

Jun 29, 2026

Jun 26, 2026

Price to earnings forward of Cartesian Therapeutics, Inc. – NASDAQ:RNAC - TradingView

Jun 26, 2026

Cabaletta Bio: The Market Sold The EULAR News, I'm Buying (NASDAQ:CABA) - Seeking Alpha

Jun 26, 2026

RNAC Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Cartesian Therapeutics, Inc. Actuals & Estimates (NASDAQ:RNAC) - TradingView

Jun 26, 2026

Enterprise value to EBIT forward of Cartesian Therapeutics, Inc. – NASDAQ:RNAC - TradingView

Jun 26, 2026

Jun 25, 2026

Price to sales forward of Cartesian Therapeutics, Inc. – GETTEX:1S70 - TradingView

Jun 25, 2026

Price to book forward of Cartesian Therapeutics, Inc. – GETTEX:1S70 - TradingView

Jun 25, 2026